Emotional Distance in Ovarian Cancer Care: Why Clinicians Retreat into the Biomedical Study: Qualitative Research Study ( Frontiers in Oncology , July 2026) | Access Full Study via Frontiers in Oncology The Bottom Line In ovarian cancer management, a patient’s sense of ownership, hope, and quality of life depends heavily on empathetic communication with their care team. However, this qualitative study examining how gynaecologists interact with ovarian cancer patients reveals a stark reality: when faced with the high mortality and recurring nature of the disease, clinicians frequently retreat into objective biomedical assessments (tumour markers, scan outputs, drug choices) while maintaining emotional distance as a self-preservation strategy. Recognising this dynamic helps support nurses understand why medical consultations often feel purely technical, highlighting the critical role nurses play in filling the emotional and holistic care gap. Key Study Insig hts Focusing on the Di...

Ovarian Clear Cell Cancer Is Different: Dual Immunotherapy Signals Promise Study: Phase II Trial of Combination Nivolumab plus Ipilimumab ( PubMed ID: 40608313 / MoST-CIRCUIT) | Access Abstract via PubMed The Bottom Line Ovarian Clear Cell Cancer (OCCC) is a distinct, uncommon type of ovarian cancer—making up about 5% to 10% of cases in Western populations (and up to 15–20% in Asian cohorts). Unlike the more common serous types, clear cell tumours are notoriously resistant to standard platinum-based chemotherapy, leaving advanced cases with a poor 5-year survival rate of ~20%. Driven by unique molecular features—including underlying DNA repair deficiencies—OCCC is an ideal target for personalised immunotherapy. Early data from an Australian-led trial evaluating a dual drug combination (Nivolumab + Ipilimumab) shows encouraging response rates in this hard-to-treat group. Disease Profile & Trial Snapshot The Clinical Hurdle: Clear cell tumours often affect younger women and freque...

Commercial Liquid Biopsy for Early Detection: Ethical Realities & Specificity Defects Report: Guardian Australia Analysis on Commercial Liquid Biopsies | Access Full Report via The Guardian The Bottom Line Direct-to-consumer advertising is currently marketing a $1,495 out-of-pocket liquid biopsy test (circulating tumour DNA) to Australian women for asymptomatic ovarian cancer. While early detection remains a critical goal, health leaders—including the Ovarian Cancer Research Foundation (OCRF)—warn that commercially offering this unapproved TGA test carries major ethical concerns and severe diagnostic limitations. With a sensitivity of ~78% and a specificity of ~94%, the test simultaneously misses a quarter of true cancers while generating thousands of false alarms in healthy women. The Two-Way Diagnostic Flaw ┌─────────────────────────────────────────────────────────────────────────┐ │ COMMERCIAL TEST PROFILE │ ├────────────────────...

Predicting Long-Term Survival in Advanced Ovarian Cancer Study: Retrospective survey of 359 women with advanced ovarian cancer. | Access Full Study via ScienceDirect The Bottom Line Long-term survival is an achievable reality for a significant subset of patients with advanced ovarian cancer. Approximately 30% of women in this group achieved long-term survival reaching the 10-year mark . Key positive survival drivers include complete surgical resection at primary cytoreduction, the presence of a BRCA mutation, and a high baseline level of general well-being and independence. Conversely, clear cell histology continues to mean poor long-term survival outcomes. Key Predictors of 10-Year Survival The survey identifies four distinct clinical and biological markers that shape the long-term horizon: Surgical Outcomes: Complete macroscopic removal of the cancer during the primary surgical procedure remains the single most impactful clinical factor for survival. The BRCA Paradox: While a BRC...

Emergency Room Ovarian Cancer Diagnoses Study: Population-based cohort of 28,204 women (England, 2017–2021). Access Full Study The Bottom Line An astonishing 40% (2 in 5) of ovarian cancer patients are diagnosed within 28 days of an emergency room admission. This represents a systemic failure that almost always results in late-stage diagnoses and poor survival rates. Who is Missing the Diagnostic Window? The data show emergency presentations aren't random; they split into two clear, vulnerable groups: The Disadvantaged Young: Younger women from low socioeconomic backgrounds facing barriers to primary medical care. The Frail Elderly: Older women with complex, competing comorbidities that mask vague cancer symptoms. The Pandemic Spike: Emergency diagnoses peaked sharply in 2020 , proving that when routine primary care access shrinks, emergency cancer presentations surge. What OCA Support Nurses Need to Know High-Distress Intake: ER-diagnosed patients skip the gradual preparatio...

Oophorectomy-Corrected Ovarian Cancer Incidence, Survival, and Mortality by Subtype, Race, Ethnicity https://tinyurl.com/tk4v75pj Ovarian cancer is declining. This decrease is mostly attributed to hormonal contraception, which means fewer lifetime menstrual cycles. This effect has been noted for the almost 60 years that hormonal contraception has been available and has increased with time as the users aged. As other forms of contraception develop, oral hormonal contraception is now used by 11% of the US population. Despite this, the incidence of ovarian cancer continues to fall ; the reasons are not clear. One suggestion is that removal of ovaries (oophorectomy) for reasons other than cancer may have the effect of reducing ovarian cancer. This study looked at the SEER cancer registry . A lmost 160000 cases of ovarian cancer were recorded during the period 2002 -2019. The rate of ovarian cancer decreased by about 2% for white women and less , about 1. 5 % for black women. The ra...

Long-Term Outcomes in Patients w ith Recurrent Ovarian Cancer and Exceptional Response to PARP Inhibitors https://tinyurl.com/y937k685 When PARP inhibitor therapy was first introduced, it was supposed to be maintenance t reatment aimed at slowing the progression of ovarian cancer. The measure of success was hel d to be progression-free s urvival ; cure was not expected with most, if not all, patients with ovarian cancer dying from the disease. It soon became clear that there was a subgroup of patients whose survival was prolonged beyond the 5-year “ cure ” marker . This was noted in all the clinical trials with up to 20% of participants in the SOLO 2 still alive 5 years later. This retrospective study was of 320 patients who were part of this group , with a history of exceptional survival . About two-thirds of them had received continual treatment with PARP inhibitors ; the others had discontinued the drug either due to carer intervention or due to adverse effects or pers...

Advances in immunotherapies in ovarian cancer https://tinyurl.com/5397dpd5 Immunotherapy acts by promoting the activity of cell-mediated immunity to target and kill cancer cells. It is  extremely effecti ve for several cancers, such as melanoma, but thus far has been ineffective for ovarian cancer, which is considered to be immunologically "cold". This editorial review  shows  why this is so and suggests  targets for more effective treatment in the future. Cell-mediated immunity acts by T cells invading the tumour microenvironment (TME) . Ovarian cancer cells prevent this from happening , usually by reinforcing the cell membrane with antigen checkpoints that prevent the infiltration of these T c ells. Immunotherapy helps to overcome this protection either by direct checkpoint blockade or by  identifying the relevant antigen and using an antibody drug combi nation to overcome the resistance and access the TME. Manipulation of T cell activity by  g...

Endometriosis and ovarian cancer risk https://tinyurl.com/36vyrxjf Endometriosis is a chronic cause of pain for about 10% of women during their reproductive life. The cause remains uncertain; initially thought to result f rom retrograde menstruation, the implanted cells found throughout the pelvis, which have a similar appearance t o the uterine epithelium, may be due to stem ce ll activation. Chronic inflammation from endometriosis has been cited as a possible cause for ovarian cancer. This study, looking at all available information using a standard method ology known as the PRISMA guidelines, suggests that the risk is low for most types of ovarian cancer, altho ugh there is an increased risk of endometrioid and clear cell cancer,  which account for about 10% of the total. Because ovarian cancer generally has a low incidence , with about 11/1000 women developing the disease during their lifetime, the overal l risk increase due to endometriosis at about 1.3 means a smal...

‘What has changed?’: Insomnia could explain the rise in early-onset hormonal cancer in women https://tinyurl.com/4ph4v97e The incidence of cancer in young people is increasing. Why remains uncertain, with obesity and pollution having been suggested as potential causes. At the recent ASCO meeting , d ata from a study were disclosed which suggested insomnia may be contributing to this increase. A retrospective 5-year study of more than 400,000 adults with insomnia looked at cancer incidence and compared the outcomes with a large control group. Women with insomnia had a significantly greater chance of developing breast, uterine and ovarian cancer . Men with insomnia seem to be more likely to have prosta t e or testicular cancer, though the evidence is incomplete. Insomnia is said to affect about 16% of the population; behaviour modification may be protective. Melatonin , often deficient in insomnia, is an oestrogen blocker . Being an insomniac looks like a health hazard.

Recurrence and Malignant Transformation After Borderline Ovarian Tumo u rs : A Systematic Review and Meta-analysis https://tinyurl.com/yk7et5rw Borderline ovarian tumours make up 10 to 20% of ovarian masses. They present at an earlier age and rarely progress to invasive cancer. Because of this, surgery for these tumours is often limited to removal of the ovarian mass with preservation of fertility. This analysis of all the available information looks at the risks of recurrence and malignant change to determine whether limited fertility-saving  surgery is harmful. M ore than 5000 women were included who underwent surgery for borderline tumours, which included complete clearance for some, with others having less radical surgery , many for preservation of fertility . Recurrence of the tumour is more likely with limited surgical clearance , with as much as a 30% chance in some instances . Those women who had radical surgery had a low risk of recurrence at about 3% . Pr...

ASCO 2026: Fasting boosts chemotherapy responses for ovarian cancer patients https://tinyurl.com/5xvffb8k A pilot clinical study has suggested that fasting before and after chemotherapy may be protective, with better survival. This group of 36 women with advanced serous ovarian cancer underwent neoadjuvant chemotherapy with three cycles of treatment. For half of the group d uring the 36 hours before chemo a nd for 24 hours afterwards, th ey underwent calorie restriction of less than 350 calories daily . The other half had normal diets. Those women who fasted had significantly lower insulin levels than the control group. Insulin plays an important role in cancer treatment; cancer cells exhibit increased insulin receptor expression, thereby triggering  an essential metabolic survival mechanism. Reducing circulating insulin causes cancer cell death. Results from the study showed an improved response to neo adjuvant chemo with better clearance. Also,  data at 18 month...